case_images: PMC11003264_01
case_images: (A) Schematic diagram of the domain structure of the EGFR-MACF1 fusion at the RNA and protein levels. (B) Computed tomography (CT) scan and three-dimensional reconstruction before and after EGFR-TKI treatment and at the latest follow-up. (C) The entire treatment procedure.
case_images: fonc-14-1347282-g001.jpg
case_images: PMC11003264_01_fonc-14-1347282-g001.jpg
case_images: f1
case_images: The EGFR-MACF1 gene included EGFR exons 1-23 and MACF1 exons 59-93 ( Figure 1A ). Re-examination by chest CT on January 31, 2023, revealed that the tumor continued to respond to the EGFR-TKI ( Figure 1B ). According to the RECIST guidelines, the patient was considered to have a partial response to almonertinib, and the patient's progression-free survival (PFS) was >9 months ( Figure 1C ).
case_images: PMC11003264_02
case_images: (A) Schematic diagram of the domain structure of the EGFR-GNAT3 fusion at the DNA and protein levels. (B) Computed tomography (CT) scan before and after treatment and after tumor progression. (C) The entire treatment procedure.
case_images: fonc-14-1347282-g002.jpg
case_images: PMC11003264_02_fonc-14-1347282-g002.jpg
case_images: f2
case_images: The EGFR-GNAT3 gene included EGFR exons 1-24 and GNAT3 exon 8 ( Figure 2A ). However, due to physical reasons specific to the patient, the drug was suspended for 2 months, after which the tumor progressed after 1 month of treatment with almonertinib (110 mg/day) ( Figure 2B ). On June 24, 2022, the patient died of severe lung infection and systemic multiple organ failure, with an overall survival (OS) <7 months ( Figure 2C ).